Isarna Therapeutics Stock

isarna-therapeutics.comHealthcareFounded: 1900Funding to Date: $131.24MM

Isarna Therapeutics is a clinical stage biotech company developing ISTH0036, a next-generation antisense to block TGF-beta 2 production, a key molecule in the pathogenesis of retinal disease.

Register for Details

For more details on financing and valuation for Isarna Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Isarna Therapeutics.

Register Today

Team

Management Team

Philippe Calais Ph.D
Chief Executive Officer
Karl-Hermann Schlingensiepen
Owner & Co-Founder

Other companies like Isarna Therapeutics in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$400.53MM
Sector
Last Round Est. Valuation
$4.26B
Sector
 
 
Sector
 
 
Sector
Last Round Est. Valuation
$1.08B